Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia

Kallesh D. Jayappa, PhD, Caroline Farrington, PhD, Vicki L. Gordon, BS, Shekhar Saha, PhD, Christopher Morris, BS, Krista M. Isaac, MD, Timothy P. Bender, PhD, Michael E. Williams, MD, Craig A. Portell, MD, Goutham Narla, MD PhD, Michael J. Weber, PhD

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-138954

Published: 2020

Journal Articles

A Multi-Drug Tolerant Phenotype Is Induced By Diverse Microenvironmental Agonists in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Kallesh D. Jayappa, DVM, PhD, Konrad J. Cios, BSc (2019), Vicki L. Gordon, BSc, Puja C. Arora, MD, Timothy P. Bender, PhD, Michael E. Williams, MD, Craig A. Portell, MD, Michael J. Weber, PhD

Blood (2018) 132 (Supplement 1): 4120.

https://doi.org/10.1182/blood-2018-99-119521

Published: 2018

Journal Articles

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L. Gordon, BSc, Goutham Narla, MD PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2018) 132 (Supplement 1): 2649.

https://doi.org/10.1182/blood-2018-99-116759

Published: 2018

Journal Articles

Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L Gordon, BS, Brian J Capaldo, PhD, Stefan Bekiranov, PhD, Julia D Wulfkuhle, Rosa I Gallagher, Emanuel F. Petricoin, PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2016) 128 (22): 754.

https://doi.org/10.1182/blood.V128.22.754.754

Published: 2016

Journal Articles

Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib

Daphne Guinn, Amy S. Ruppert, MAS, Kami J. Maddocks, MD, Samantha Jaglowski, MD MPH, Amber L. Gordon, Thomas S. Lin, MD PhD, Richard A. Larson, Guido Marcucci, MD, Erin K Hertlein, PhD, Jennifer A. Woyach, MD, Amy J. Johnson, PhD, John C. Byrd, MD

Blood (2014) 124 (21): 3297.

https://doi.org/10.1182/blood.V124.21.3297.3297

Published: 2014

Journal Articles

Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions

Craig A. Portell, MD, Mark Axelrod, PhD, L. Kyle Brett, MD, Vicki L Gordon, BS, Brian Capaldo, Jeffrey C Xing, Stephan Bekiranov, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2014) 124 (21): 509.

https://doi.org/10.1182/blood.V124.21.509.509

Published: 2014

Journal Articles

Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms

Satoru Otsuru, Patricia L. Gordon, Kengo Shimono, Reena Jethva, Roberta Marino, Charlotte L. Phillips, Ted J. Hofmann, Elena Veronesi, Massimo Dominici, Masahiro Iwamoto, Edwin M. Horwitz

Blood (2012) 120 (9): 1933–1941.

https://doi.org/10.1182/blood-2011-12-400085

Published: 2012

Includes: Supplemental data

Journal Articles

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Sarah E. M. Herman, Amber L. Gordon, Erin Hertlein, Asha Ramanunni, Xiaoli Zhang, Samantha Jaglowski, Joseph Flynn, Jeffrey Jones, Kristie A. Blum, Joseph J. Buggy, Ahmed Hamdy, Amy J. Johnson, John C. Byrd

Blood (2011) 117 (23): 6287–6296.

https://doi.org/10.1182/blood-2011-01-328484

Published: 2011

Journal Articles

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

Sarah E. M. Herman, Rosa Lapalombella, Amber L. Gordon, Asha Ramanunni, Kristie A. Blum, Jeffrey Jones, Xiaoli Zhang, Brian J. Lannutti, Kamal D. Puri, Natarajan Muthusamy, John C. Byrd, Amy J. Johnson

Blood (2011) 117 (16): 4323–4327.

https://doi.org/10.1182/blood-2010-11-315705

Published: 2011

Journal Articles

Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-δ Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia

Sarah E.M. Herman, Rosa Lapalombella, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Amber L. Gordon, Asha Ramanunni, Brian Lannutti, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2010) 116 (21): 1821.

https://doi.org/10.1182/blood.V116.21.1821.1821

Published: 2010

Journal Articles

The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals

Sarah E.M. Herman, Amber L. Gordon, Emilia Mahoney, MD, PhD, Samantha M. Jaglowski, MD, Kristie A. Blum, MD, Joseph Buggy, PhD, Ahmed Hamdy, MD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2010) 116 (21): 1385.

https://doi.org/10.1182/blood.V116.21.1385.1385

Published: 2010

Journal Articles

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Sarah E. M. Herman, Amber L. Gordon, Amy J. Wagner, Nyla A. Heerema, Weiqiang Zhao, Joseph M. Flynn, Jeffrey Jones, Leslie Andritsos, Kamal D. Puri, Brian J. Lannutti, Neill A. Giese, Xiaoli Zhang, Lai Wei, John C. Byrd, Amy J. Johnson

Blood (2010) 116 (12): 2078–2088.

https://doi.org/10.1182/blood-2010-02-271171

Published: 2010

Journal Articles

The Effect of Increasing CD34+ Cell Doses on Time to Engraftment after Autotransplantation for Hematologic Malignancies.

V. Singh, J. Krishnamurthy, O. Frankfurt, Andrew M Evens, DO, MS, J. Altman, L. Gordon, S. Singhal, M. Tallman, S. Williams, J. Winter, J. Mehta

Blood (2008) 112 (11): 1115.

https://doi.org/10.1182/blood.V112.11.1115.1115

Published: 2008

Journal Articles

Optimizing the CD34+ Cell Dose for Allogeneic Transplantation.

J. Mehta, Andrew M Evens, DO, MS, J. Altman, O. Frankfurt, Martin Tallman, MD, L. Gordon, S. Williams, J. Winter, J. Krishnamurthy, S. Duffey, V. Singh, R. Meagher, S. Singhal

Blood (2008) 112 (11): 1118.

https://doi.org/10.1182/blood.V112.11.1118.1118

Published: 2008

Journal Articles

The Hematopoietic Cell Transplantation Comorbidity Index: No Effect on Outcome of Reduced-Intensity Allografts.

O. Frankfurt, J. Altman, J. Krishnamurthy, Andrew M Evens, DO, MS, L. Gordon, S. Singhal, M. Tallman, S. Williams, J. Winter, S. Duffey, V. Singh, R. Meagher, J. Mehta

Blood (2008) 112 (11): 1119.

https://doi.org/10.1182/blood.V112.11.1119.1119

Published: 2008

Journal Articles

Cytomegalovirus Seropositivity Does Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation with Intensive Monitoring and Modern Anti-Viral Therapy

S. Singhal, Rucha Mehta, J. Krishnamurthy, S. Duffey, O. Frankfurt, Andrew M Evens, DO, MS, J. Altman, M. Tallman, L. Gordon, S. Williams, J. Winter, J. Mehta

Blood (2008) 112 (11): 4370.

https://doi.org/10.1182/blood.V112.11.4370.4370

Published: 2008

Journal Articles

Actual (ABW) or Ideal (IBW) Body Weight to Calculate CD34+ Cell Dose in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Myeloma?

J. Krishnamurthy, V. Singh, O. Frankfurt, Andrew M Evens, DO, MS, J. Altman, L. Gordon, S. Singhal, M. Tallman, S. Williams, J. Winter, J. Mehta

Blood (2008) 112 (11): 4455.

https://doi.org/10.1182/blood.V112.11.4455.4455

Published: 2008

Journal Articles

Factors Affecting the Results of Allogeneic Hematopoietic Stem Cell Transplantation in Hematologic Malignancies

J. Mehta, O. Frankfurt, J. Altman, Andrew M Evens, DO, MS, L. Gordon, M. Tallman, S. Williams, J. Winter, J. Krishnamurthy, D. Grinblatt, L. Kaminer, S. Singhal

Blood (2008) 112 (11): 4386.

https://doi.org/10.1182/blood.V112.11.4386.4386

Published: 2008

Journal Articles

Oral Busulfan and Cyclophosphamide or IV Busulfan and Fludarabine for Allogeneic HSCT in Hematologic Malignancies?.

J. Altman, N. Venepalli, J. Monreal, K. Rashid, L. Gordon, J. Winter, S. Williams, M. Tallman, O. Frankfurt, A. Evens, S. Singhal, J. Mehta

Blood (2006) 108 (11): 2940.

https://doi.org/10.1182/blood.V108.11.2940.2940

Published: 2006

Journal Articles

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Treating Hyperuricemia in Patients with Hematologic Malignancies.

S. Trifilio, A. Evens, L. Gordon, S. Singhal, M. Tallman, J. Mehta

Blood (2005) 106 (11): 3123.

https://doi.org/10.1182/blood.V106.11.3123.3123

Published: 2005

NARROW

Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia

A Multi-Drug Tolerant Phenotype Is Induced By Diverse Microenvironmental Agonists in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib

Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions

Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-δ Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia

The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

The Effect of Increasing CD34+ Cell Doses on Time to Engraftment after Autotransplantation for Hematologic Malignancies.

Optimizing the CD34+ Cell Dose for Allogeneic Transplantation.

The Hematopoietic Cell Transplantation Comorbidity Index: No Effect on Outcome of Reduced-Intensity Allografts.

Cytomegalovirus Seropositivity Does Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation with Intensive Monitoring and Modern Anti-Viral Therapy

Actual (ABW) or Ideal (IBW) Body Weight to Calculate CD34+ Cell Dose in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Myeloma?

Factors Affecting the Results of Allogeneic Hematopoietic Stem Cell Transplantation in Hematologic Malignancies

Oral Busulfan and Cyclophosphamide or IV Busulfan and Fludarabine for Allogeneic HSCT in Hematologic Malignancies?.

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Treating Hyperuricemia in Patients with Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only